Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis  by Paller, Amy S. et al.
Long-term safety and efficacy of etanercept in children
and adolescents with plaque psoriasis
Amy S. Paller, MD,a Elaine C. Siegfried, MD,b David M. Pariser, MD,c Kara Creamer Rice, MS,d
Mona Trivedi, MD,d Jan Iles, MD,d David H. Collier, MD,d Greg Kricorian, MD,d and Richard G. Langley, MDe
Chicago, Illinois; St Louis, Missouri; Norfolk, Virginia; Thousand Oaks, California;
and Halifax, Nova Scotia, CanadaFrom
an
C
U
Re
U
This
of
O
Discl
ho
m
Ph
in
Ph
ce
C
m
LP
Ja
C
tio
280Background: There are no systemic therapies approved in the United States to treat pediatric psoriasis.Objective: We sought to evaluate long-term safety and efficacy of etanercept in children and adolescents
with moderate to severe plaque psoriasis.Methods: This 5-year, open-label extension study enrolled patients aged 4 to 17 years who had
participated in a 48-week parent study. End points included occurrence of adverse events (AEs) and serious
AEs including infections, and rates of 75% and 90% improvement in Psoriasis Area and Severity Index score
and clear/almost clear on static physician global assessment.Results: Of 182 patients enrolled, 181 received etanercept and 69 completed 264 weeks. Through week
264, 161 (89.0%) patients reported an AE, most commonly upper respiratory tract infection (37.6%),
nasopharyngitis (26.0%), and headache (21.5%). Seven patients reported 8 serious AEs; only 1 (cellulitis)
was considered treatment-related. No cases of opportunistic infections or malignancy were reported. Rates
of 75% improvement in Psoriasis Area and Severity Index score (;60%e70%) and 90% improvement in
Psoriasis Area and Severity Index score (;30%e40%) and static physician global assessment status clear/
almost clear (;40%e50%) were maintained through week 264.Limitations: The number of patients remaining on study at week 264 was small.Conclusion: Etanercept in pediatric patients was generally well tolerated and efficacy was maintained in
those who remained in the study for up to 264 weeks. ( J Am Acad Dermatol 2016;74:280-7.)
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Paller et al 281The overall annual incidence of psoriasis in
children and adolescents in the United States (from
birth to 18 years of age) was estimated to be 41 cases
per 100,000 person-years during the period from
1970 through 1999, and the annual incidence
increased during that time.1 Approximately one third
of adult patients with psoriasis report the develop-
ment of psoriasis symptoms before adulthood.2,3CAPSULE SUMMARY
d A 48-week etanercept study in patients
with pediatric psoriasis demonstrated
promising tolerability and efficacy.
d This open-label, 264-week extension
study showed no unexpected adverse
events and efficacy was maintained.
d Etanercept could be an option for
pediatric psoriasis; access is limited by
lack of disease-specific labeling.From 1979 through 2007, pe-
diatric patients had approxi-
mately 3.8 million health
care visits for their psoriasis,
representing a considerable
health care burden.4
Comorbidities associated
with pediatric psoriasis
include metabolic syndrome,
hypertension, hyperlipid-
emia, diabetes mellitus,
rheumatoid arthritis, and
Crohn’s disease.5,6 Pediatric
patients have impaired
health-related quality of life
(HRQOL) from their psoriasis, particularly with
respect to emotional and school functioning.7,8 The
cumulative life course impairment as a result of
psoriasis, which affects the ability for individuals to
fulfill their full lifetime potential, is particularly
devastating for adolescents and young adults
compared with patients who have adult-onset
psoriasis.9
Therapies currently approved by the US Food and
Drug Administration (FDA) for the treatment of
pediatric psoriasis in the United States include only
a small number of topical agents with labeled
indications limited to children 12 years of age or
older. Of the interventions used for the treatment of
moderate to severe plaque psoriasis in adults
(phototherapy, methotrexate, cyclosporine, oral
retinoids, or biologic agents) none is FDA-
approved for children with moderate to severe
psoriasis. Access to effective systemic treatments
is limited for children and adolescents with
psoriasis because of the lack of data and labeled
indication.10
Etanercept is a soluble tumor necrosis factor
receptor fusion protein that reversibly binds to tumor
necrosis factor. Etanercept is approved for the
treatment of adults with moderately to severely
active rheumatoid arthritis, active psoriatic arthritis,
active ankylosing spondylitis, and moderate to
severe plaque psoriasis. Etanercept has also been
approved since 1999 in the United States to
treat children with moderately to severely active
polyarticular juvenile idiopathic arthritis (JIA) downto 2 years of age.11 Etanercept has been shown to be
effective for the treatment of JIA at 0.8 mg/kg
once weekly (maximum 50 mg) with a favorable
safety profile during long-term therapy.12,13 We
now report 5-year results from an open-label
extension (OLE) study to examine the safety and
efficacy of etanercept (0.8 mg/kg) for treating
moderate to severe plaque psoriasis in pediatricpatients enrolled at 4 to
17 years of age.
METHODS
Study design
This study (study
20050111) was an OLE
of the parent 20030211
study (ClinicalTrials.gov no.
NCT00078819), a 48-week
study that enrolled 211
patients with moderate to
severe plaque psoriasis
between 4 and 17 years of
age.14 The parent study wasconducted in 3 consecutive phases: a 12-week
double-blind, placebo-controlled phase; a 24-week
open-label phase; and a 12-week double-blind
withdrawal-retreatment phase (Supplemental Fig 1;
available at http://www.jaad.org).14 During the OLE
study, patients received etanercept once weekly
at 0.8 mg/kg (maximum 50 mg) for up to
264 weeks. Use of topical standard-of-care therapy,
including mild- to moderate-potency topical
corticosteroids, was allowed during the study.
Patients were allowed to discontinue etanercept
from week 96 if they had a static physician global
assessment (sPGA) status of clear/almost clear
(score of 0/1), and could restart etanercept at the
discretion of the investigator. An interim analysis at
week 96 has been reported.15 Patients who enrolled
in the OLE study were followed up through week
264 or until they turned 18 years of age, whichever
came last.
The study was conducted in accordance with
International Conference on Harmonization Good
Clinical Practice regulations and guidelines and with
the Declaration of Helsinki. Institutional review
boards at each participating site approved the study
protocol and amendments, and written informed
consent was provided by parents or legal guardians
of each patient before initiation of study-related
procedures. This study was registered under
ClinicalTrials.gov no. NCT00141921 on August 31,
2005, and the first patient was enrolled on August 11,
2005. This analysis includes data through February
22, 2012.
Fig 1. Plaque psoriasis, patient disposition. OLE, Open-
label extension.
Abbreviations used:
AE: adverse event
CDC: Centers for Disease Control and
Prevention
FDA: Food and Drug Administration
HRQOL: health-related quality of life
JIA: juvenile idiopathic arthritis
OLE: open-label extension
PASI: Psoriasis Area and Severity Index
PASI 75: 75% improvement in Psoriasis Area and
Severity Index score
PASI 90: 90% improvement in Psoriasis Area and
Severity Index score
SAE: serious adverse event
sPGA: static physician global assessment
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Children and adolescents with moderate to severe
plaque psoriasis who completed study 20030211 or
who had not completed the parent study but had
achieved substantial benefit from etanercept on or
after week 12 with no serious adverse event (SAE)
or other clinically significant adverse event (AE)
considered related to etanercept were eligible to
participate in the OLE study. Substantial benefit in
the parent study was defined as achieving a 50% or
greater improvement from baseline in Psoriasis Area
and Severity Index (PASI) score.
End points
The primary end point was the incidence of AEs
and SAEs, including infectious events. A SAE was
defined as an event that resulted in persistent or
significant disability or incapacity or death, was life
threatening, required hospitalization, or was a
congenital anomaly or birth defect. Additional
key safety end points included the incidence of
antinuclear antibody and anti-etanercept antibody
formation. The key efficacy end points included
the incidence of 75% improvement in PASI score
(PASI 75) and 90% improvement in PASI score (PASI
90) from baseline of the parent study and patients
achieving clear/almost clear (score 0/1) on the sPGA.
Statistical considerations
Patients who received 1 or more doses of
etanercept in the extension study were included in
all safety and efficacy analyses. An analysis of
growth (height, weight, and body mass index
percentile based on growth charts from the
Centers for Disease Control and Prevention
[CDC]16) was performed on the subset of patients
who stayed in the study through year 5 and did not
reach 20 years of age (the maximum age in the CDC
growth charts). No imputation was used for missing
data.RESULTS
Patients
Of 211 patients enrolled in the parent study,14 182
patients enrolled in the OLE study, 181 received
etanercept, 140 completed 96 weeks,15 and 69
patients completed 264 weeks on study. Of these
69 patients, 28 continued further follow-up past
week 264 until they reached 18 years of age
(Fig 1). There were 621.0 patient-years of exposure
to etanercept during the OLE study. Baseline
demographics have been previously reported15;
briefly, the mean (SD) age was 12.8 (3.5) years,
51%weremale, and 76%were white. Mean psoriasis-
affected body surface area, PASI scores, and sPGA
scores were improved at the entry into the OLE study
compared with the baseline of the parent study
(Table I). Only 5 patients elected to discontinue
etanercept after week 96 because they were rated as
clear/almost clear (score 0/1) on the sPGA and 3 of
Table I. Patient demographics and clinical
characteristics
Characteristic
All patients
(N = 182)
Weight, mean, kg (SD) [range]
at parent study baseline
62.3 (27.3) [17.7-168.3]
Height, mean, cm (SD) [range]
at parent study baseline
155.9 (18.6) [104.2-190.5]
BMI, mean, percentile (SD)
[range] at parent study
baseline
75.9 (27.5) [7.4-100]
Psoriasis-affected BSA, mean,
% (SD) [range]
Parent study baseline 25.9 (15.6) [10-95]
OLE study baseline 7.2 (10.2) [0-68]
PASI, mean, score (SD) [range]
Parent study baseline 18.7 (6.9) [12-57]
OLE study baseline 4.8 (4.8) [0-27]
sPGA score, n (%)
Parent study baseline
0 0
1 0
2 1 (0.5)
3 121 (66.5)
4 56 (30.8)
5 4 (2.2)
OLE study baseline
0 16 (8.8)
1 65 (35.7)
2 69 (37.9)
3 27 (14.8)
4 3 (1.6)
5 0
Unknown 2 (1.1)
BMI, Body mass index; BSA, body surface area; OLE, open-label
extension; PASI, Psoriasis Area and Severity Index; sPGA, static
physician global assessment.
Table II. Height, weight, and body mass index
percentiles for children and adolescents who
completed 5 years on study and did not reach
20 years of age*
Characteristic
Patients
(N = 43)
n Mean percentile (SD) [range]
Height
Parent study baseline 43 56.3 (26.3) [9.2-98.7]
OLE study baseline 43 57.2 (26.5) [8.7-96.8]
Wk 48 41 57.7 (26.1) [11.3-99.2]
Wk 96 43 57.5 (27.3) [7.9-98.9]
Wk 144 43 57.7 (27.0) [5.1-100.0]
Wk 192 43 56.1 (26.4) [8.4-99.4]
Wk 240 41 56.6 (28.3) [6.4-98.9]
Wk 264 43 58.2 (28.6) [5.9-99.5]
Weight
Parent study baseline 43 66.4 (27.7) [8.6-99.5]
OLE study baseline 43 68.5 (26.7) [9.4-99.7]
Wk 48 41 69.3 (26.6) [6.8-99.9]
Wk 96 43 67.8 (26.3) [6.0-99.9]
Wk 144 43 69.5 (26.0) [4.0-99.9]
Wk 192 43 69.2 (26.8) [2.5-99.9]
Wk 240 41 68.4 (26.9) [2.2-99.9]
Wk 264 43 70.3 (25.3) [1.9-99.9]
BMI
Parent study baseline 43 64.8 (31.3) [7.7-99.4]
OLE study baseline 43 78.4 (22.5) [29.3-99.6]
Wk 48 41 66.0 (29.1) [10.9-99.5]
Wk 96 43 64.6 (29.1) [0.3-99.6]
Wk 144 43 65.3 (30.1) [0.2-99.6]
Wk 192 43 65.7 (29.5) [1.2-99.8]
Wk 240 41 64.4 (30.6) [1.1-99.9]
Wk 264 43 65.7 (28.2) [2.9-99.9]
BMI, Body mass index; OLE, open-label extension.
*Percentiles were based on growth charts from the Centers for
Disease Control and Prevention, which have a maximum age of
20 years.
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common reasons for discontinuing from the OLE
study were consent withdrawn (n = 42), loss to
follow-up (n = 19), and noncompliance (n = 17)
(Fig 1). Of the 42 patients who withdrew consent, 16
provided a reason: approximately half withdrew for
reasons of inconsistent results or decline in efficacy
and the others were unable or did not want to
continue study visits because of relocation, travel
burden, or they wanted to take a medication break.
For the subset of 43 patients who remained on the
study through year 5 and did not turn 20 years of age
(because CDC percentile data were only available up
to age 20 years), mean percentiles for height, weight,
and body mass index were above the 50th percentile
and remained relatively constant throughout the
study (Table II). Results for all patients showed a
similar trend (data not shown).Safety
A total of 161 (89.0%) patients reported an AE
through week 264. The most commonly reported
AEs were upper respiratory tract infection (37.6%),
nasopharyngitis (26.0%), and headache (21.5%)
(Table III). Injection-site reactions were reported
by 16 (8.8%) patients. Through week 264, 7 patients
reported 8 SAEs (Table IV) including 2 patients
with infectious events (cellulitis and infectious
mononucleosis). Four events were reported before
week 96,15 and 4 (cellulitis, infectious mononucle-
osis, osteonecrosis, and thyroid cyst) were reported
during the subsequent 168 weeks. Only 1 SAE
(cellulitis) was considered by the investigator to be
related to the investigational product. Six patients
withdrew from the study between weeks 96 and 264
because of the following AEs (none was a SAE):
Table III. Incidence and corresponding exposure-
adjusted rates of adverse events occurring in[5%
of patients receiving etanercept through week 264
AE
Patients*
n (%)
Eventsy
n
Exposure-
adjusted
event rate/100
patient-years
Upper respiratory
tract infection
68 (37.6) 144 23.2
Nasopharyngitis 47 (26.0) 93 15.0
Headache 39 (21.5) 55 8.9
Acne 33 (18.2) 21 3.4
Streptococcal pharyngitis 27 (14.9) 36 5.8
Sinusitis 24 (13.3) 31 5.0
Skin papilloma 24 (13.3) 17 2.7
Cough 22 (12.2) 26 4.2
Influenza 21 (11.6) 28 4.5
Oropharyngeal pain 20 (11.0) 32 5.2
Bronchitis 18 (9.9) 19 3.1
Nasal congestion 17 (9.4) 26 4.2
Pyrexia 17 (9.4) 27 4.3
Pharyngitis 15 (8.3) 20 3.2
Arthralgia 14 (7.7) 11 1.8
Gastroenteritis 14 (7.7) 14 2.3
Viral gastroenteritis 14 (7.7) 15 2.4
Psoriasis worsening 14 (7.7) 18 2.9
Nausea 13 (7.2) 15 2.4
Ear infection 12 (6.6) 17 2.7
Procedural pain 12 (6.6) 16 2.6
Urinary tract infection 12 (6.6) 16 2.6
Upper abdominal pain 11 (6.1) 21 3.4
Contact dermatitis 11 (6.1) 11 1.8
Diarrhea 11 (6.1) 12 1.9
Ligament sprain 11 (6.1) 13 2.1
Viral upper respiratory
tract infection
11 (6.1) 18 2.9
AE, Adverse event.
*Data represent the number of patients with an event at any time
during the study, regardless of whether the patient was on or off
etanercept at the time of the event.
yData represent the number of events that occurred during
exposure to etanercept.
Table IV. Incidence and corresponding exposure-
adjusted rates of serious adverse events occurring
in patients receiving etanercept
SAE
Patients*
n (%)
Eventsy
n
Exposure-
adjusted
event rate/100
patient-years
Abortion induced 1 (0.6) 1 0.2
Anxiety 1 (0.6) 1 0.2
Cellulitis 1 (0.6) 1 0.2
Infectious mononucleosis 1 (0.6) 1 0.2
Osteonecrosisz 1 (0.6) 2 0.3
Postoperative intestinal
obstructionx
1 (0.6) 1 0.2
Thyroid cyst 1 (0.6) 1 0.2
SAE, Serious adverse event.
*Data represent the number of patients with an event at any time
during the study, regardless of etanercept exposure.
yData represent the number of events that occurred during
exposure to etanercept.
zA patient with history of congenital acetabular dysplasia and
avascular necrosis of both hips reported 2 separate events of
osteonecrosis approximately 1 y apart.
xA patient with history of congenital bladder exstrophy underwent
successful Mitrofanoff procedure and reported intestinal
obstruction approximately 5 wk after surgery.
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psoriasis worsening (n = 1), sinusitis (n = 1), and
VIIth nerve paralysis (n = 1). Through week 264
there were 2 cases of herpes zoster. No opportunistic
infections or malignancies were reported.
A total of 18 (10.7%) patients tested positive for
anti-etanercept antibodies during the study,
including 8 (6%) patients at week 48, 8 (7%) at
week 96, 5 (5%) at week 144, 7 (7%) at week 168,
and 4 (7%) at week 264. No patient developed
neutralizing antibodies through week 264. Rates of
PASI 75 and PASI 90 responses did not appear to be
different in patients with anti-etanercept antibodies
compared with the overall patient population(Supplemental Fig 2; available at http://www.jaad.
org). Similarly, the mean age of patients with anti-
etanercept antibodies was similar to the overall
population (data not shown). Antinuclear antibody
was detected in 11 (6%) patients at baseline,
0 patients at week 48, 3 (2%) at week 96, 5 (3%)
at week 144, 6 (3%) at week 168, and 2 (1%) at
week 264.
Efficacy
Efficacy outcomes of PASI score responses and
sPGA scores through week 96 have been previously
reported.14,15 The percentages of patients achieving
PASI 75 and PASI 90 responses from baseline in the
parent study remained relatively constant at approx-
imately 60% to 70% and 30% to 40%, respectively, at
week 96 throughweek 264 (Fig 2,A andB). Similarly,
the percentage of patients who achieved sPGA status
of clear/almost clear (score 0/1) remained relatively
constant at approximately 40% to 50% from week 96
through week 264 (Fig 2, C ). Rates of PASI 75
responses were slightly lower in patients categorized
as obese or overweight compared with patients at
healthy weight (Supplemental Fig 3; available at
http://www.jaad.org).
DISCUSSION
To our knowledge, this was the largest published
study with the longest follow-up of any biologic
Fig 2. Plaque psoriasis, efficacy outcomes in children and adolescents treated with etanercept.
The percentage of patients with 75% improvement in Psoriasis Area and Severity Index score
(PASI 75) (A), 90% improvement in Psoriasis Area and Severity Index score (PASI 90) (B), and
static physician global assessment (sPGA) status of clear/almost clear (score 0/1) (C) from week
96 through week 264 is shown. The number of patients with available data is shown below
each graph. Data are reported as observed, without imputation for missing data. Error bars
represent 95% confidence interval (CI ).
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retention in efficacy over 5 years in these patients
was particularly encouraging, as the growing
children were restricted to a maximum dose of50 mg weekly regardless of body mass index.
Obesity appears to be a risk factor for psoriasis in
children and adolescents,17-19 and higher weight is
associated with greater severity of disease.19 These
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therapeutic option for this patient population.
Etanercept has been approved for the treatment of
JIA in children and adolescents for approximately
15 years, and although that patient population is
clinically different from patients with psoriasis, the
safety profile of etanercept is similar in both
populations. In general, the use of tumor necrosis
factor blockers is associated with increased rates of
infection in both adult and pediatric patients.20 In the
original randomized, controlled clinical study to
evaluate the safety and efficacy of etanercept in
children with JIA, the most common AEs were
injection-site reactions (39%), upper respiratory tract
infections (35%), and headache (20%). During that
study and in the following 8 years of follow-up in the
subsequent OLE study, 9 medically important
infections were reported for a rate of 0.03 events
per patient-year.21-23 Importantly, rates of medically
important infections did not increase with increased
exposure to etanercept.23 Recent safety data from
registries24,25 and prospective studies26,27 of patients
with JIA also note an increased risk of infections,
which are usually mild in severity.
The long-term efficacy of etanercept for patients
with psoriasis appears to be consistent between
pediatric and adult populations. PASI 75 responses
were achieved and maintained in approximately
60% of the children and adolescents who remained
on etanercept for up to 5 years in our study.
This result is similar to the rate of PASI 75
responses reported in adults receiving etanercept at
a stable dose of 50 mg weekly for up to 72 weeks.28
The rate of sPGA responses of clear/almost clear at
week 96 was approximately 50%, which was
higher than the rate from a pooled analysis of
long-term data in adults with psoriasis (;30%)
who received etanercept for up to 48 months.29
Rates of PASI and sPGA responses appear to be
relatively stable with long-term treatment with
etanercept in both pediatric and adult patients with
psoriasis.
A limitation of the study was the relatively small
number of patients in the study overall and in the
number of patients who remained on etanercept
through the OLE study. Rare safety events that may
only occur in children and adolescents would be
unlikely to be observed with so few patient-years of
exposure. In addition, as patients had strict eligibility
requirements for entry into the parent study,
these results are not generalizable to the overall
population of pediatric patients with psoriasis.
Effective treatment for moderate to severe psori-
asis is important for all patients. The stigmatizing
effect of psoriasis may especially impact youngpatients who have not developed coping skills to
deal with their disease.9 Moreover, major life
decisions occur during adolescence and early
adulthood, including the choices of careers,
marriage, and childbearing; impairments influencing
these decisions affect an individual’s cumulative life
course and are largely irreversible.9 Children and
adolescents require early effective treatment to
minimize the negative effects of psoriasis.
Etanercept has been shown to improve HRQOL in
the pediatric population included in this study with
both short-term14 and long-term15 treatment.
Although HRQOL measures used in clinical trials
do not provide data on cumulative life course
impairment, they do provide a snapshot of the
patient’s perspective on their HRQOL.
In conclusion, etanercept provided clinical
benefit for up to 264 weeks in children and adoles-
cents with moderate to severe plaque psoriasis. No
new safety concerns were observed with long-term
treatment in this patient population.
Dikran Toroser, PhD (Amgen Inc), and Julia R. Gage,
PhD (Gage Medical Writing LLC; supported by Amgen),
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Supplemental Fig 1. Study schema. aDuring the double-blind treatment phase, patients were
randomized (1:1) to etanercept or placebo weekly. After week 4, patients could enter an escape
group and receive open-label etanercept through week 12 if their Psoriasis Area and Severity
Index (PASI) score either increased by[50% over baseline and by a minimum of 4 points at 1
visit or increased by[25% and by a minimum of 4 points at each of 2 consecutive visits. bAll
patients, including those who entered the escape group during weeks 4 through 12, received
open-label etanercept. Patients who did not achieve a 50% improvement in PASI score (PASI
50) at week 24 or a 75% improvement in PASI score (PASI 75) at week 36 could discontinue the
study or add topical standard-of-care therapy and continue to receive open-label etanercept
until week 48. cAt week 36, patients with a PASI 50 at week 24 or PASI 75 at week 36 were
randomized (1:1) to etanercept or placebo. Patients who lost their PASI 75 response resumed
open-label etanercept through week 48. EOS, End of study; OLE, open-label extension.
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Supplemental Fig 2. The 75% improvement in Psoriasis Area and Severity Index score
(PASI 75) and 90% improvement in Psoriasis Area and Severity Index score (PASI 90) responses
in patients who developed anti-etanercept antibodies. The percentage of patients who
achieved PASI 75 (A) and PASI 90 (B) response from baseline of the parent study is shown
for patients who developed anti-etanercept antibodies (open circles) and all patients (closed
diamonds). No patient developed neutralizing antibodies. CI, Confidence interval.
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Supplemental Fig 3. The percentage of patients categorized as healthy weight (body mass
index [BMI] 5th-84th percentile*; open diamonds), overweight (BMI 85th-94th percentile; gray
squares), and obese (BMI$95th percentile; black triangles) who achieved a 75% improvement
in Psoriasis Area and Severity Index score (PASI 75) response from baseline of the parent study.
*Barlow SE; Expert Committee. Expert Committee recommendations regarding the prevention,
assessment, and treatment of child and adolescent overweight and obesity: summary report.
Pediatrics 2007;120(Suppl):S164-92. CI, Confidence interval.
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